Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Telmisartan

Criteria

Inclusion Criteria:

• Patients of both sexes with essential hypertension and a minimum age of 18 years

Exclusion Criteria: (Not applicable)